In biotech communications, understanding your audience can evolve as quickly as your scientific innovations. This makes staying up to date on audience sentiment crucial. Whether it’s ensuring that healthcare providers understand your science as an FDA decision approaches, or how the investor community perceives your competitive advantages with an impending IPO, these insights can be essential data points for your communications strategy. With that in mind, the question becomes, how? Enter social listening. Recently, TBC’s Digital Marketing Manager Hannah Clark discussed the value of social listening in biotech. She covered: - What social listening entails - How it can play out in the biotech landscape - What essential tactics to use to optimize your social listening strategy Give it a read on our blog: https://lnkd.in/eYd_8eht
Ten Bridge Communications
Public Relations and Communications Services
Boston, MA 4,425 followers
We guide biotech through the big moments.
About us
We work with biotech innovators at all stages of growth and development, whether they are launching anew or advancing a potentially transformative medicine through regulatory approval and beyond. Our work is guided by a deep curiosity about our partners’ science and patient focus and a commitment to elevating them and their message to the world. Relationships – both with our partners and across biotech – are critical ingredients of our success.
- Website
-
https://www.tenbridgecommunications.com/
External link for Ten Bridge Communications
- Industry
- Public Relations and Communications Services
- Company size
- 11-50 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Company launches, corporate branding & creative services, strategic communications planning & execution, patient engagement & advocacy support, product approval & launch communications, and milestone-related media and communications
Locations
-
Primary
One Beacon Street
8th Floor
Boston, MA 02108, US
Employees at Ten Bridge Communications
-
Chris Railey
Vice President at Ten Bridge Communications
-
Florence Chan, SHRM-SCP
Head of Human Resources at Ten Bridge Communications
-
Leslie (Priest) Humbel
Strategic healthcare communicator, marketer and client manager
-
Josh Madej, MS, MBA
Wellness Entrepreneur I Care-tech Founder I Biotech Marketer I Former Patient & Caregiver
Updates
-
Earlier this year, we had the privilege of partnering with #TBCPartner Clasp Therapeutics to launch their company and announce their Series A. Clasp is developing off-the-shelf precision immuno-oncology therapeutics to target hard-to-treat tumors with absolute specificity. Their launch was incredibly impactful, receiving some great recognition across key media outlets. Some of the communications highlights included: - 19 feature stories - 37 total pieces of coverage - Gained 2,500 LinkedIn followers in the first 24 hours following launch Learn more about our collaboration with Clasp in our recent case study: https://lnkd.in/gNxB8H3P
Clasp Therapeutics » Ten Bridge Communications
tenbridgecommunications.com
-
Tune in to the latest Labiotech.eu #BeyondBiotechPodcast to hear how #TBCPartner Molecular Partners is contributing to “The Radiotherapeutics Boom.” CEO Patrick Amstutz and SVP Research and Technology Daniel Seiner talk with host Jim Cornall and radiopharmaceutical expert Ken Herrmann about Molecular Partners’ #RadioDARPin platform, their preclinical data and the future of the field.
What’s up with the recent radiotherapeutics boom? 💥 Radiopharmaceuticals have been a hot topic of late. These drugs can diagnose as well as treat diseases. 💉 🎙️ Labiotech has been in conversation with radiopharmaceuticals expert Ken Herrmann, Molecular Partners’ CEO Patrick Amstutz, and SVP of R&D Daniel Steiner, about the challenges facing radiopharma and how they’re being addressed. Molecular Partners’ radioligand therapy is being investigated to treat small-cell lung carcinoma, a highly aggressive form of lung cancer. 🫁 🎧 Tune into the latest episode of the Beyond Biotech Podcast to find out more! 👇 https://lnkd.in/dpHzDjJf #BeyondBiotechPodcast #radiotherapeutics #radiopharmaceuticals #cancertreatment #medicalinnovation #healthcaretrends #biotechnews
-
Congratulations to #TBCPartner Verona Pharma! Yesterday’s FDA approval of their drug for the maintenance treatment of #COPD marks a significant advance for patients as the first inhaled product with a novel mechanism of action in more than two decades – a game-changing advancement in the standard of care. https://lnkd.in/e9d4s8GH
With FDA nod, Verona's Ohtuvayre is set to Jack up the COPD market
fiercepharma.com
-
#TBCPartner X4 Pharmaceuticals' momentum continues with the announcement of interim data from its ongoing Phase 2 trial of mavorixafor, the company’s oral CXCR4 antagonist, in chronic neutropenia. Chronic neutropenia is a rare condition in which patients’ low levels of neutrophils in the blood lead to higher risk of developing infections and reduced quality of life. It’s exciting to see progress toward a new treatment option for these patients.
Today, we announced positive interim data from our ongoing Phase 2 trial evaluating the safety and efficacy of our product candidate in people with #ChronicNeutropenia (CN). We also announced that we’ve started screening patients for enrollment into our pivotal Phase 3 trial, the 4WARD study, to evaluate our product candidate in people with congenital, acquired primary autoimmune, or idiopathic CN. We’re hosting a webinar today at 8:00 am ET and will detail the interim results, feature clinical experts in the treatment of CN, and discuss the 4WARD study. Learn more here: https://lnkd.in/eaDtEtT6 #Progress4Patients
-
-
#TBCPartner Intellia Therapeutics, Inc. continues to push the boundaries of #CRISPR genome editing. While the goal of their therapies in development is to be one-and-done, new data suggest that the editing technology can potentially be redosed, which may have advantages in certain contexts.
Can #CRISPR be given twice? Small study from Intellia Therapeutics, Inc. suggests it can. But why would you want a CRISPR therapy twice? Isn't this supposed to be one-and-done? Yes, but there are some cases where 2 or 3 doses could help. My story for Endpoints News explains: https://lnkd.in/exhh8u2R #biotech #geneediting #genetherapy #drugdevelopment #geneticmedicine #lipidnanoparticle
Can CRISPR be given twice? Small study from Intellia suggests it can
https://endpts.com
-
It was a privilege to work alongside #TBCPartner HC Bioscience, Inc. on their new brand and website. A leader in #tRNA-based therapies, they are pioneering a new approach in protein editing, with programs in #hemophilia and #DMD. Their new site dives into the science behind tRNA, their platform for treating genetic diseases, and their lead programs. Give the new site a look.
We’re excited to unveil our new website! It serves as a hub to showcase HC Bioscience’s pioneering work in engineering tRNAs to overwrite faulty genes. Our protein editing approach corrects disease-causing mutations without altering DNA or mRNA, with one therapeutic tRNA having the potential to address a broad spectrum of genetically driven diseases. Explore our site to learn more about our #tRNA technology, our amazing team, and our collective drive to transform patients’ lives. [https://bit.ly/4evG8iD]
-
We want to extend our congratulations to #TBCPartner Sarepta Therapeutics and the entire Duchenne community on last night’s monumental FDA decision. With the expanded label, Sarepta’s gene therapy is now approved for the majority of patients with Duchenne muscular dystrophy.
BREAKING: Today, we announced the U.S. FDA has expanded the product label for our gene therapy and more people may be able to receive treatment. Intended for U.S. audiences
-
-
We are thrilled to welcome Jesena Kalabokis to team TBC via Project Onramp! Jesena joins us from the University of Massachusetts Amherst where she is currently majoring in journalism with a minor in environmental science. In her free time at UMass, she manages a radio station where she plays a different genre of music every week. Welcome, Jesena – we’re looking forward to an exciting and engaging summer!
-
-
Last week #TBCPartner X4 Pharmaceuticals' Founder, CEO & President Paula Ragan, Ph.D., was joined by BiotechTV's Brad Loncar in X4’s vibrant Boston HQ for a discussion on the company's newly FDA approved treatment for an ultra-rare disease and what's on the horizon.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: X4 Pharmaceuticals' CEO Paula Ragan, Ph.D. on the recent launch of XOLREMDI for WHIM Syndrome and CXCR4 inhibition more broadly for additional indications. She describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4 will have in chronic neutropenia towards the end of the month. Full video: https://lnkd.in/gzMpmhiB BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent